Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2923 | Placebo (carrier control) Wiki | 1.00 |
| drug1775 | Hydroxychloroquine Wiki | 0.10 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
ULSC-CV-01 is a clinical trial that comprises both Phase 1 and Phase 2a, which will be conducted sequentially. This trial will evaluate the safety and potential efficacy of allogeneic Umbilical Cord Lining Stem Cells (ULSC), which are a type of umbilical cord tissue derived mesenchymal stem cells (MSC), with intravenous (IV) administration in hospitalized patients with acute respiratory distress syndrome (ARDS) due to COVID-19.
Description: Number of subjects with a DLT event during or within 24 hours after ULSC infusion [Dose Limiting Toxicities are treatment-emergent suspected adverse reactions graded as severe, such as severe infusion-related hypersensitivity toxicities of grade ≥3, and any treatment-emergent serious adverse event (SAE) will be investigated to determine if DLT.]
Measure: Incidence of Dose Limiting Toxicity (DLT) Time: 24 hoursDescription: Number of subjects with a DLT event, suspected adverse reaction, or any serious adverse event (SAE) within 1 week of each ULSC infusion
Measure: Incidence of Dose Limiting Toxicity (DLT), suspected adverse reaction (SAR), or serious adverse event (SAE) Time: 1 weekDescription: Treatment-emergent adverse events (AE; incidence, grade, and assessment of relatedness or causality) and serious adverse events (SAE) during the study up to 1-month follow-up
Measure: Treatment-emergent adverse events (AE) and serious adverse events (SAE) Time: 1 monthDescription: Treatment-emergent adverse events (AE; incidence, grade, and assessment of relatedness or causality) and serious adverse events (SAE) during the study and up to the 12-month follow-up
Measure: Treatment-emergent adverse events (AE) and serious adverse events (SAE) Time: 12 monthsDescription: Times to transitions between levels of COVID-19 related ARDS as defined by the Berlin Definition of ARDS
Measure: Levels of COVID-19 related ARDS as defined by the Berlin Definition of ARDS Time: 1 monthDescription: Changes in SpO2/FiO2 ratio or pAO2/FiO2 ratio compared to baseline, measured daily at a minimum; oxygenation index daily when on ventilator
Measure: Changes from baseline pulse oximetric saturation SpO2/FiO2 ratio or arterial oxygen pressure pAO2/FiO2 ratio Time: 1 monthDescription: Number of ventilator-free days (VFD) in period of 1 month from study treatment
Measure: Number of ventilator-free days (VFD) Time: 1 monthDescription: Changes in CBC with differential from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment
Measure: Changes in Complete Blood Count (CBC) with differential from baseline Time: 1 month, 2 months, 3 months, 6 months, and 12 monthsDescription: Changes in blood glucose (mg/dL) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment
Measure: Changes in levels of blood glucose (mg/dL) from baseline Time: 1 month, 2 months, 3 months, 6 months, and 12 monthsDescription: Changes in levels of sodium (mEq/L) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment
Measure: Changes in levels of sodium (mEq/L) from baseline Time: 1 month, 2 months, 3 months, 6 months, and 12 monthsDescription: Changes in levels of potassium (mEq/L) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment
Measure: Changes in levels of potassium (mEq/L) from baseline Time: 1 month, 2 months, 3 months, 6 months, and 12 monthsDescription: Changes in levels of blood urea nitrogen (BUN; mg/dL) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment
Measure: Changes in levels of blood urea nitrogen (BUN; mg/dL) from baseline Time: 1 month, 2 months, 3 months, 6 months, and 12 monthsDescription: Changes in levels of alanine transaminase (ALT; U/L) from baseline to 1 month, 2 months, 3 months, 6 months, and 12 months after study treatment
Measure: Changes in levels of alanine transaminase (ALT; U/L) from baseline Time: 1 month, 2 months, 3 months, 6 months, and 12 monthsDescription: Change in Urinalysis (UA) at baseline and 1 month after study treatment to assess for presence and qualitative proteinuria
Measure: Change in Urinalysis (UA) from baseline Time: 1 monthAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports